In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AZ and Merck: Moving Forward Cautiously

Executive Summary

A year after Merck & Co. Inc. and AstraZeneca PLC announced their innovative collaboration on the clinical development of two early-stage targeted cancer therapies, both companies say the project remains on track. To date the collaboration remains the sole example of two big drug makers collaborating in such close fashion on such early stage products. The companies were willing to take the leap in order to accelerate development of what they hope will be an effective targeted treatment in an emerging, highly competitive, but frustrating area of cancer research.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts